Can This New Discovery Bring Us One Step Closer To ‘Universal’ Cancer Treatment?

After the failure of the conventional T-cell therapy to cure solid tumors, scientists believe that they’ve finally discovered its modified version to cure a wide range of cancers.

 

The study has been performed by scientists at Cardiff University and describes a new way to kill different types of cancer with the help of T-cell receptors (TCRs).

 

This new method involves a different type of TCR that recognizes a particular molecule called MR1 present on the surface of cancer cells and kills them.

 

The study was performed in an animal model of mice with human cancer cells and a human immune system.

 

Currently, the new TCR method is under continuous assessment to fully understand its underlying mechanism and assess its safety in patients.

 

If this new finding continues to bear success, it will set a new base or a universal T-cell medication that will greatly reduce the costs of identification, generation, and production of T-cell.

 

3 Key Points

1.  A new type of TCR has been brought to light which is argued to kill cancer cells by recognizing a specific molecule on their surfaces.

2. This new method has raised the prospects of being the single best treatment to kill different types of cancer including cancers of lung, skin, colon, blood, prostate, bone, breast, ovary, cervix, and kidney.

3. The study has been regarded as a great step for modifying the cancer immunotherapy.

 

Professor Andrew Sewell, from Cardiff University’s School of Medicines, says “Current TCR-based therapies can only be used in a minority of patients with a minority of cancers. Cancer-targeting via MR1-restricted T-cells is an exciting new frontier – it raises the prospect of  ‘one-size-fits-all’ cancer treatment.” 

Article source: http://bit.ly/2TwMyoZ

#ClinicalResearch, #DrugDevelopment, #Pharmaceutical

P.S. Want to learn more about cancer studies? Always stay informed by getting summarized articles straight to your inbox for FREE. Click here to learn more.

Latest news

ACTide by Nubilaria against COVID-19

DECEIVER trial for COVID-19 related ARDS intensive care

Read more
Nubilaria ACTide @ Direct to Patient digital experience

Direct-to-Patient and Virtual Clinical Trials – Digital Experience

Read more
Nubilaria ACTide @ BIO Digital

BIO Digital

Read more

Want more information about our solutions?
Contact us today.

I've read and accept theTerms and Conditions and the Privacy Policy
   I would like to receive information about products and services via traditional mail, telephone, email and automated communication systems